Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ELGN-2112 for feeding intolerance and intestinal malabsorption in preterm infants
NL-OMON53803Phase 3Not yet recruiting
- Sponsor
- Elgan Pharma
- Start
- Aug 2023
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in preterm birth and intestinal malabsorption comparing ELGN-2112 with Placebo (2 arms). Primary endpoint: Time to full enteral feeding. Planned start Aug 2023; status: not yet recruiting.
02
Drugs
elgn-gi
03
Conditions
preterm birthintestinal malabsorption
Beyond the preview
Go deeper on NL-OMON53803.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53803.